|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Rabies | |||||
| 2 | More general conditions related to this trial | ||||
| Mononegavirales Infections | |||||
| Rhabdoviridae Infections | |||||
| RNA Virus Infections | |||||
| Virus Diseases | |||||
| 3 | Interventions listed in this trial | ||||
| CL184 | |||||
| HRIG | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Immunoglobulins | |||||
| 5 | More general drug interventions related to this trial | ||||
| Immunologic Factors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| 6 | Sponsors listed in this trial | ||||
| Crucell Holland BV | |||||